Neuland Laboratories has delivered a strong FY26 performance, reporting total income of Rs. 2,053.1 crore and EBITDA of Rs. 603.4 crore, marking a year of sharp operational acceleration and margin expansion.

 

The pharmaceutical manufacturer, which supplies active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions across around 80 countries, said the year ended March 31, 2026, concluded “on a strong note in line with our original expectations.”

 

Commenting on the performance, Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories, said, “We are pleased with the fact that we have ended FY26 on a strong note in line with our original expectations. 

 

"There is good business visibility in the short to medium term anchored by commercial and near-commercial molecules. Our focus on execution discipline, customer satisfaction, and protection of business fundamentals is central to ensuring this phase of growth. At the same time, we are laying the groundwork for growth beyond this horizon. 

 

"Key elements of this foundation are the investments in Peptide Manufacturing as well as the new R&D Centre, which are proceeding according to plan. Our Business Development strategy is aligned to the investments and is focused on bringing in the right kind of projects that support high quality, sustainable growth.”

Q4 surge drives full-year momentum

 

The company’s Q4 FY26 results showed a dramatic jump across key metrics:

 

Total Income surged to Rs. 788.7 crore, up 134.9% year-on-year

 

EBITDA soared to Rs. 319.4 crore, a 448.6% jump from the previous year

 

EBITDA margin expanded sharply to 40.5%, compared with 17.3% a year earlier

 

Profit Before Tax rose to Rs. 287.0 crore, up 636.6% year-on-year

 

Profit After Tax climbed to Rs. 212.5 crore, up 666.3% year-on-year

 

The quarter also reflected strong sequential momentum, with EBITDA rising 275.8% QoQ and PAT surging over 425%.

 

Margin expansion was equally striking, with PBT margin rising to 36.4% from 11.6% a year ago, underscoring stronger operating leverage and improved business mix.

 

Growth story anchored in capacity build-out

Management highlighted continued visibility in near-term business, driven by commercial and near-commercial molecules. Strategic investments in peptide manufacturing and a new R&D centre remain on track, forming the backbone of the company’s next growth phase.

 

The company’s business development focus, management said, is aligned with these investments and aimed at securing “high quality, sustainable growth” over the medium to long term.